Form 4: Intra-Cellular Therapies Director Joel Marcus Reports Stock Option Exercise and Share Acquisition

Director Joel Marcus exercised stock options and acquired shares of Intra-Cellular Therapies, Inc. at a price of $63.79 per share.

Summary

• On February 24, 2025, Joel Marcus, a director of Intra-Cellular Therapies, Inc. (ITCI), exercised stock options to acquire 7,009 shares of common stock at a price of $63.79 per share.
• Following the transaction, Marcus directly owns 48,238 shares of ITCI common stock.
• Marcus also indirectly owns 10,000 shares through Alexandria Real Estate Equities, Inc., where he serves as Executive Chairman & Founder.
• Marcus disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein.
• A Power of Attorney was executed on September 26, 2024, granting authority to several individuals to act on Marcus's behalf for SEC filings.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects a standard insider transaction (option exercise) which is neither overtly positive nor negative.

Positives

• The exercise of stock options by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Insider transactions are closely watched by investors as they can provide insights into management's perspective on the company's valuation and future performance. Option exercises are a normal part of executive compensation.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholders if it signals confidence from a company director.

Key Dates